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ABSTRACT: Despite the importance of enantiopure chiral sulfoxides, few methods exist that allow for their deracemization.
Here, we show that an enantiopure sulfoxide can be produced from the corresponding racemate using Viedma ripening involving
rearrangement-induced racemization. The suitable candidate for Viedma ripening was identiﬁed from a library of 24 chiral
sulfoxides through X-ray structure determination. Starting from the racemic sulfoxide, an unprecedented application of a 2,3-
sigmatropic rearrangement type racemization in a Viedma ripening process allowed for complete deracemization.
■ INTRODUCTION
Single chirality is a key feature of life and hence of utmost
importance in the production of active pharmaceutical
ingredients in the pharmaceutical industry. In the case of chiral
drugs, it is generally one enantiomer that has the desired
physiological eﬀects, whereas its mirror image is inactive or
even has harmful consequences.1 An important class of drugs
consists of chiral sulfoxides, where a sulfur instead of a carbon
atom is the tetrahedral center of chirality. The best-known
example of a chiral sulfoxide is probably esomeprazole, the
number two selling drug in 2013 in the United States
(marketed as Nexium). This drug acts as a proton pump
inhibitor, reducing stomach acid production.2 Esomeprazole is
an enantiopure sulfoxide that is produced on an industrial scale
by asymmetric oxidation of the corresponding sulﬁde.3 It
contains only the (S)-enantiomer and was found to be more
active than the racemate, known as omeprazole.4,5 Obtaining an
enantiopure compound, however, is generally not straightfor-
ward, since (achiral) synthesis will yield both enantiomers in
equal amounts, while enantioselective methods in many cases
cannot be easily applied. In the majority of cases, resolution
using diasteriomeric salt formation is applied to obtain the
desired enantiomer, which, however, results in a maximum
yield of 50%. As an alternative, a deracemization method might
be applied, allowing yields of a single enantiomer in up to 100%
yield.6 Viedma ripening is such a method that allows the
conversion of a racemic mixture of solids into a single
enantiomer in theoretically 100% yield.7,8 It involves grinding
of a suspension of racemic conglomerate crystals in
combination with racemization in solution, resulting in
complete deracemization of the solid phase. The scope of
Viedma ripening, however, has so far remained limited due to
the lack of suitable racemization strategies.9 The majority of
examples consist of base-induced racemization through
deprotonation, or involve a redox reaction. Consequently,
examples of molecules that have been deracemized with
Viedma ripening include amino acids10 and derivatives,11 and
metalorganic complexes.12 In addition, the group of Hak̊ansson
demonstrated Viedma ripening and successive oxidation on a
ruthenium-sulﬁde complex.13 However, due to the limitations
in racemization methods, and despite the relevance of chiral
sulfoxides in drugs, no such molecules have yet been
deracemized using Viedma ripening. The purpose of our
study is therefore to expand the scope of Viedma ripening to
this important class of chiral molecules. In this article, we
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describe the route that we used to screen for a suitable sulfoxide
and disclose the ﬁrst example of deracemization of a sulfoxide
using Viedma ripening.
■ RESULTS AND DISCUSSION
A few challenges need to be faced before this particular case of
Viedma ripening can be applied. First, the molecule of interest
must be able to undergo racemization in solution. While the
majority of sulfoxides racemize at temperatures over 200 °C,14
allylic sulfoxides racemize at much lower temperatures (even
below 50 °C15) since they are prone to undergo a 2,3-
sigmatropic rearrangement, known as the Mislow−Evans
rearrangement (Figure 1).16−18 Such an intramolecular
rearrangement is unprecedented as the racemization mecha-
nism in Viedma ripening.
A second requirement for Viedma ripening is that the
enantiomers crystallize as separate crystals, i.e., form a racemic
conglomerate. For the majority (∼90%) of compounds,
however, the enantiomers crystallize in the same crystal, i.e.,
form a racemic compound. Thus, the ﬁrst step in this project is
to identify a conglomerate allylic sulfoxide. Since no such
conglomerate has been posted in the Cambridge Structural
Database (CSD) up to now, we ﬁrst performed a screening. Salt
formation has been described as a route for ﬁnding
conglomerate crystals.19 However, since many sulfoxides are
not compatible with salt formation, we decided to engage in a
library synthesis.
A series of 24 sulfoxides was synthesized to ensure a
reasonable chance of ﬁnding a conglomerate (Figure 2, see
Supporting Information for a complete overview). To identify
sulfoxides displaying conglomerate behavior, crystals suitable
for X-ray analysis were grown using slow solvent evaporation.
From the 24 synthesized compounds, crystals could be grown
of 14 of them, from which we found that compound 1
crystallized as a racemic conglomerate. All other compounds
crystallized as racemic compounds (Figure 2).
Compound 1 was subsequently used for the Viedma ripening
experiments. The speed of racemization of allylic chiral
sulfoxides is highly solvent dependent.20 We found that
racemization of compound 1 takes place at room temperature
in apolar solvents such as toluene and diethyl ether, while the
optical purity of the sulfoxide can be retained in polar solvents
such as methanol (t1/2 > 4 days at RT).
By using toluene at room temperature as a solvent and
starting from completely racemic conditions, an enantiomeric
excess (ee) of 12% was obtained after a period of over a month.
These promising results prompted us to investigate the
racemization kinetics, in order to reduce the deracemization
time. We found a relatively high barrier for the racemization of
1 in toluene at room temperature according to both density
functional theory (DFT) calculations (ΔH = 18.1 kcal/mol)21
and temperature dependent selective exchange spectroscopy
experiments (ΔH = 21.2 kcal/mol). This barrier leads to a
relatively long racemization half-life (t1/2 = 6.9 h) and results in
slow deracemization. We therefore decided to increase the
temperature in order to reduce the deracemization time.
Figure 1. An allylic sulfoxide can reversibly rearrange into an achiral
sulfenate via a 2,3-sigmatropic rearrangement, resulting in solution
phase racemization of the chiral sulfoxide.
Figure 2. A series of 24 allylic chiral sulfoxides were synthesized, of which crystal structures could be determined for 14 of them (space groups are
given after the compound number). Of these 14, only compound 1 crystallized as a racemic conglomerate.
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By changing the solvent system to reﬂuxing diethyl ether (t1/2
= 6.3 h at RT and 1.1 h at reﬂux, bp 35 °C) and creating a small
initial bias (around 1% ee), complete deracemization of 1 could
be achieved in just 8 days (Figure 3).
In order to further decrease the deracemization time, the
temperature was further increased to 50 °C. Since this
temperature exceeds the boiling point of diethyl ether, the
solvent was changed to toluene. Under these conditions,
however, deracemization experiments of compound 1 were
unsuccessful due to melting of the compound. When the
solution was then cooled again, 1 recrystallized as a diﬀerent
polymorph with a lower melting point. We found that this low
melting polymorph was in fact a metastable racemic compound
(see Supporting Information).
We have shown in a previous study that the speed of Viedma
ripening can be increased using such a metastable racemic
compound in combination with enantiopure seed crystals.22
Hence, we investigated whether this same approach could be
applied to reduce the deracemization time of chiral sulfoxide 1.
Indeed, by starting from the racemic compound in combination
with enantiopure seed crystals in reﬂuxing diethyl ether, the
deracemization time could be further decreased to 3 days
(Figures 3 and 4).
■ CONCLUSION
We have demonstrated that Viedma ripening can be used to
deracemize chiral sulfoxides. By synthesizing 24 chiral allylic
sulfoxides which spontaneously racemize through a 2,3-
signatropic rearrangement at elevated temperatures in solution,
one racemic conglomerate compound, suitable for Viedma
ripening, was identiﬁed. Chiral ampliﬁcation was achieved for
this compound by simply heating a suspension of the molecule
under grinding conditions.
This experimentally facile route allows for the straightforward
preparation of an enantiopure allylic sulfoxide. That this was
done for one compound out of a library of 24 candidates might
be considered as a limitation. However, similar enantiopure
allylic sulfoxides have been used as chiral pool starting
materials, and as chiral auxiliaries for the synthesis of
enantiopure acids and esters.23 Therefore, one deracemized
compound can be the starting point for several enantiopure
compounds. In addition, the present Viedma ripening screening
not only demonstrates the preparation of a speciﬁc enantiopure
sulfoxide, but also shows a general route that can be followed
for the deracemization of other compounds.
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